Exogenous dendritic cell homing to draining lymph nodes can be boosted by mast cell degranulation

Cellular Immunology

Volumn 263, Issue 2, 2010, Pages 204-211

  Ren, Shu Rong ^a,b   Xu, Li Bin ^b   Wu, Zhi Yuan ^b   Du, Jun ^b   Gao, Mei Hua ^a   Qu, Chun Feng ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Dendritic cells; Homing to draining lymph nodes; Mast cell degranulation

Indexed keywords

COMPOUND 48-80; DENDRITIC CELL VACCINE; HEPATITIS B SURFACE ANTIGEN; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL HOMING; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IMMUNIZATION; LYMPHATIC DRAINAGE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CELL; TH1 CELL; TH2 CELL;

ANIMALS; CELL DEGRANULATION; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; LYMPH NODES; MAST CELLS; MICE; MICE, INBRED C57BL; P-METHOXY-N-METHYLPHENETHYLAMINE; RECEPTORS, LYMPHOCYTE HOMING;

MUS;

EID: 77953364053     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.03.017     Document Type: Article

References (39)

1. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
2. MartIn-Fontecha A., Sebastiani S., Hopken U.E., Uguccioni M., Lipp M., Lanzavecchia A., Sallusto F. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 2003, 198:615-621.
3. Nencioni A., Grunebach F., Schmidt S.M., Muller M.R., Boy D., Patrone F., Ballestrero A., Brossart P. The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 2008, 65:191-199.
4. Berger T.G., Schultz E.S. Dendritic cell-based immunotherapy. Curr. Top. Microbiol. Immunol. 2003, 276:163-197.
5. Figdor C.G., de Vries I.J., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 2004, 10:475-480.
6. Lesterhuis W.J., de Vries I.J., Adema G.J., Punt C.J. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann. Oncol. 2004, 15(Suppl. 4):iv145-iv151.
7. Okada N., Mori N., Koretomo R., Okada Y., Nakayama T., Yoshie O., Mizuguchi H., Hayakawa T., Nakagawa S., Mayumi T., Fujita T., Yamamoto A. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005, 12:129-139.
8. Nair S., McLaughlin C., Weizer A., Su Z., Boczkowski D., Dannull J., Vieweg J., Gilboa E. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 2003, 171:6275-6282.
9. Verdijk P., Aarntzen E.H., Punt C.J., de Vries I.J., Figdor C.G. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin. Biol. Ther. 2008, 8:865-874.
10. Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 2005, 5:617-628.
11. Alvarez D., Vollmann E.H., von Andrian U.H. Mechanisms and consequences of dendritic cell migration. Immunity 2008, 29:325-342.
12. Dieu M.C., Vanbervliet B., Vicari A., Bridon J.M., Oldham E., Ait-Yahia S., Briere F., Zlotnik A., Lebecque S., Caux C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 1998, 188:373-386.
13. Ohl L., Mohaupt M., Czeloth N., Hintzen G., Kiafard Z., Zwirner J., Blankenstein T., Henning G., Forster R. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004, 21:279-288.
14. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
15. Robbiani D.F., Finch R.A., Jager D., Muller W.A., Sartorelli A.C., Randolph G.J. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000, 103:757-768.
16. Scandella E., Men Y., Gillessen S., Forster R., Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002, 100:1354-1361.
17. Luft T., Jefford M., Luetjens P., Toy T., Hochrein H., Masterman K.A., Maliszewski C., Shortman K., Cebon J., Maraskovsky E. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002, 100:1362-1372.
18. Galli S.J., Nakae S., Tsai M. Mast cells in the development of adaptive immune responses. Nat. Immunol. 2005, 6:135-142.
19. Jawdat D.M., Rowden G., Marshall J.S. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J. Immunol. 2006, 177:1755-1762.
20. Jawdat D.M., Albert E.J., Rowden G., Haidl I.D., Marshall J.S. IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J. Immunol. 2004, 173:5275-5282.
21. McLachlan J.B., Shelburne C.P., Hart J.P., Pizzo S.V., Goyal R., Brooking-Dixon R., Staats H.F., Abraham S.N. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat. Med. 2008, 14:536-541.
22. McLachlan J.B., Hart J.P., Pizzo S.V., Shelburne C.P., Staats H.F., Gunn M.D., Abraham S.N. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat. Immunol. 2003, 4:1199-1205.
23. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., Muramatsu S., Steinman R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176:1693-1702.
24. Angeli V., Llodra J., Rong J.X., Satoh K., Ishii S., Shimizu T., Fisher E.A., Randolph G.J. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004, 21:561-574.
25. Ferry X., Brehin S., Kamel R., Landry Y. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 2002, 23:1507-1515.
26. Heib V., Becker M., Warger T., Rechtsteiner G., Tertilt C., Klein M., Bopp T., Taube C., Schild H., Schmitt E., Stassen M. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 2007, 110:946-953.
27. Bytautiene E., Vedernikov Y.P., Saade G.R., Romero R., Garfield R.E. IgE-independent mast cell activation augments contractility of nonpregnant and pregnant guinea pig myometrium. Int. Arch. Allergy Immunol. 2008, 147:140-146.
28. Banchereau J., Schuler-Thurner B., Palucka A.K., Schuler G. Dendritic cells as vectors for therapy. Cell 2001, 106:271-274.
29. Kedl R.M., Kappler J.W., Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol. 2003, 15:120-127.
30. Hernandez J., Aung S., Redmond W.L., Sherman L.A. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 2001, 194:707-717.
31. + T cell tolerance. J. Exp. Med. 2002, 196:1627-1638.
32. Echtenacher B., Mannel D.N., Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996, 381:75-77.
33. Malaviya R., Ikeda T., Ross E., Abraham S.N. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996, 381:77-80.
34. Suto H., Nakae S., Kakurai M., Sedgwick J.D., Tsai M., Galli S.J. Mast cell-associated TNF promotes dendritic cell migration. J. Immunol. 2006, 176:4102-4112.
35. McGowen A.L., Hale L.P., Shelburne C.P., Abraham S.N., Staats H.F. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 2009, 27:3544-3552.
36. Paton W.D. Compound 48/80: a potent histamine liberator. Br. J. Pharmacol. Chemother. 1951, 6:499-508.
37. Angeli V., Ginhoux F., Llodra J., Quemeneur L., Frenette P.S., Skobe M., Jessberger R., Merad M., Randolph G.J. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006, 24:203-215.
38. Mazzoni A., Siraganian R.P., Leifer C.A., Segal D.M. Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J. Immunol. 2006, 177:3577-3581.
39. Theiner G., Gessner A., Lutz M.B. The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo. Immunobiology 2006, 211:463-472.